Bioventix

Historical price data

Bioventix is a specialist biotechnology company focused on the development and supply of high-affinity sheep monoclonal antibodies for the global in-vitro diagnostics (IVD) industry. Founded in 2004 and listed on the London AIM market, its core strategy is to identify diagnostic assays with unmet needs for better antibodies, develop superior SMAs, and license them to major diagnostic partners, generating stable, high-margin royalty revenue. The company has achieved consistent profitability and growth by leveraging its unique technological niche to become a critical, behind-the-scenes supplier to nearly all major global immunodiagnostics companies.

Proprietary platform for generating and engineering high-affinity sheep monoclonal antibodies (SMAs), specifically optimized for performance in diagnostic immunoassays, particularly for challenging small-molecule and conserved protein targets.

Bioventix competes with rodent antibody suppliers and in-house IVD R&D teams by offering superior, high-affinity sheep antibodies for technically challenging targets. Its deep expertise, proven integration into commercial assays, and IP create a defensible niche, though it faces potential competition from alternative species platforms (e.g., nanobodies).